| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.79 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,922,851 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,660,378 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
29 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2016-01-07 |
4 |
B |
$1.22 |
$761,526 |
D/D |
625,689 |
3,058,173 |
2.45 |
- |
|
| Plunkett Matthew |
EVP, Chief Business Officer |
• – – |
2016-01-04 |
4 |
AS |
$1.20 |
$12,134 |
D/D |
(10,000) |
610,084 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2015-12-30 |
4 |
AS |
$1.26 |
$125,710 |
D/D |
(100,000) |
2,258,302 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2015-12-28 |
4 |
AS |
$1.29 |
$12,921 |
D/D |
(10,000) |
2,358,302 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2015-12-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(236,858) |
669,489 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2015-12-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(583,217) |
2,368,302 |
|
- |
|
| Singer Jack W |
EVP, Chief Scientific Officer |
• • – |
2015-12-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(236,858) |
1,069,992 |
|
- |
|
| Singer Jack W |
EVP Global Medical Affairs |
• • – |
2015-12-18 |
4 |
AS |
$1.17 |
$17,673 |
D/D |
(15,000) |
1,306,850 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2015-12-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,320) |
513,186 |
|
- |
|
| Telling Fred |
Director |
– • – |
2015-12-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,320) |
377,694 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2015-12-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(87,481) |
254,693 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2015-12-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,320) |
296,324 |
|
- |
|
| Love Richard L |
Director |
– • – |
2015-12-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,320) |
472,129 |
|
- |
|
| Plunkett Matthew |
EVP, Corporate Development |
• – – |
2015-12-04 |
4 |
AS |
$0.99 |
$9,969 |
D/D |
(10,000) |
620,084 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2015-11-27 |
4 |
AS |
$1.23 |
$12,253 |
D/D |
(10,000) |
2,951,519 |
|
- |
|
| Singer Jack W |
EVP, Global Medical Affairs |
• • – |
2015-11-27 |
4 |
AS |
$1.20 |
$18,157 |
D/D |
(15,000) |
1,321,850 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2015-11-19 |
4 |
AS |
$1.10 |
$16,891 |
D/D |
(15,000) |
906,347 |
|
- |
|
| Plunkett Matthew |
EVP, Corporate Development |
• – – |
2015-11-04 |
4 |
AS |
$1.37 |
$13,814 |
D/D |
(10,000) |
630,084 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2015-10-30 |
4 |
AS |
$1.35 |
$351,520 |
D/D |
(260,000) |
2,961,519 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2015-10-29 |
4 |
AS |
$1.38 |
$14,073 |
D/D |
(10,000) |
921,347 |
|
- |
|
| Singer Jack W |
EVP, Global Medical Affairs |
• • – |
2015-10-23 |
4 |
AS |
$1.61 |
$24,335 |
D/D |
(15,000) |
1,336,850 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2015-10-22 |
4 |
AS |
$1.58 |
$15,800 |
D/D |
(10,000) |
931,347 |
|
- |
|
| Plunkett Matthew |
EVP, Corporate Development |
• – – |
2015-10-05 |
4 |
AS |
$1.52 |
$15,204 |
D/D |
(10,000) |
640,084 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2015-09-30 |
4 |
S |
$1.45 |
$196,649 |
D/D |
(135,620) |
342,174 |
|
- |
|
| Love Richard L |
Director |
– • – |
2015-09-30 |
4 |
S |
$1.45 |
$19,853 |
D/D |
(13,660) |
530,449 |
|
- |
|
229 Records found
|
|
Page 6 of 10 |
|
|
